A&O Shearman Advises XGEN Venture on Investment in EpilepsyGTx

"A&O Shearman advised XGEN Venture in its participation in a Series A financing for UK gene‑therapy biotech EpilepsyGTx. The round, which included XGEN Venture, the British Business Bank and a global biopharmaceutical company, will fund first‑in‑human Phase 1/2a studies of EPY201 and further pipeline development."

A&O Shearman advised XGEN Venture in connection with its participation in the Series A financing of EpilepsyGTx. EpilepsyGTx, a UK biotechnology company focused on research and development of innovative gene therapies for the treatment of refractory epilepsy, announced a Series A funding round to advance its lead programme, EPY201, into Phase 1/2a clinical studies. The financing round included investment from XGEN Venture, a life sciences‑focused venture capital fund, the British Business Bank and a global biopharmaceutical company. The funding will enable the company to conduct first‑in‑human Phase 1/2a trials to assess the safety and efficacy of EPY201 across a broad population of patients with focal drug‑resistant epilepsy (FRE). EpilepsyGTx will also use further financing to develop an additional pipeline of innovative gene therapies targeting refractory epilepsy and disorders of neuronal hyperexcitability. A&O Shearman represented XGEN Venture with a cross‑border team from its Milan and London offices, composed by: partner Emanuele Trucco (lead), and associates Filippo Linzi and Aabynn Cha.

A&O Shearman Advises XGEN Venture on Investment in EpilepsyGTx

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads